nipah
viru
niv
hendra
viru
hev
relat
zoonot
paramyxovirus
belong
henipaviru
hnv
genu
caus
sever
enceph
respiratori
ill
fatal
rate
classifi
biosafeti
level
select
unlik
sever
paramyxovirus
hnv
broad
speci
tropism
case
canin
distemp
infect
anim
least
six
mammalian
pteropid
fruit
bat
fli
fox
appear
predomin
natur
reservoir
host
sinc
first
outbreak
hev
australia
niv
malaysia
hev
repeatedli
infect
hors
australia
result
human
foodborn
mediat
niv
spillov
occur
nearli
everi
year
furthermor
niv
outbreak
occur
philippin
besid
asia
oceania
detect
antihnv
antibodi
human
pteropu
bat
africa
contin
document
niv
hev
outbreak
occur
suggest
futur
hnv
zoonot
emerg
like
although
two
billion
peopl
live
region
threaten
potenti
hnv
outbreak
clinic
approv
vaccin
specif
therapeut
pathogen
paramyxovirus
deliv
genom
host
cytoplasm
fuse
lipid
envelop
cellular
membran
initi
infect
process
requir
concert
action
two
surfac
glycoprotein
attach
ghhn
fusion
f
set
paramyxoviru
entri
machineri
apart
class
fusion
protein
g
type
ii
homotetramer
transmembran
protein
ectodomain
compris
stalk
ctermin
head
latter
domain
respons
bind
f
homotrimer
type
transmembran
protein
synthes
prematur
precursor
cleav
cathepsin
l
endocyt
recycl
yield
matur
disulfidelink
viral
fusion
protein
believ
exist
kinet
trap
metast
conform
viru
upon
bind
niv
g
propos
undergo
conform
chang
lead
f
trigger
insert
f
hydrophob
fusion
peptid
target
subsequ
refold
stabl
postfus
f
conform
drive
merger
viral
host
membran
form
pore
genom
deliveri
cell
cytoplasm
shown
paramyxovirus
paramyxoviru
ghhn
f
glycoprotein
main
target
humor
immun
respons
neutral
antibodi
key
vaccineinduc
protect
mechan
measl
viru
among
wellcharacter
antihnv
g
neutral
monoclon
antibodi
mab
previous
isol
human
phage
display
librari
shown
neutral
known
strain
niv
moreov
protect
ferret
african
green
monkey
hevniv
lethal
challeng
administ
sever
day
post
antif
mous
polyclon
antibodi
hybridomasecret
mab
shown
protect
hamster
niv
hev
demonstr
immun
mice
prefus
niv
f
hev
f
led
strong
homotyp
serum
neutral
titer
lower
heterotyp
titer
wherea
postfus
f
fail
elicit
robust
neutral
far
inform
avail
epitop
recogn
hnv
f
mab
potenti
use
therapeut
human
guid
revers
vaccinolog
initi
previous
isol
hybridoma
secret
murin
mab
recogn
prefus
niv
f
hev
f
glycoprotein
design
report
clone
sequenc
human
demonstr
bound
high
affin
prefus
niv
f
hev
f
neutral
assay
carri
contain
show
potent
inhibit
niv
hev
infect
target
cell
determin
cryoelectron
microscopi
cryoem
structur
niv
f
trimer
complex
found
antibodi
bind
prefusionspecif
quaternari
epitop
conserv
niv
f
hev
f
structur
data
combin
ftrigger
membran
fusion
assay
demonstr
lock
f
prefus
conform
prevent
membran
fusion
via
molecular
stapl
provid
molecular
rational
potenc
result
defin
critic
neutral
epitop
surfac
niv
hev
f
glycoprotein
pave
way
futur
use
prophylaxi
therapeut
niv
hevinfect
individu
understand
humor
immun
respons
direct
hnv
f
glycoprotein
clone
sequenc
neutral
mab
hybridoma
previous
obtain
upon
mice
immun
prefus
niv
f
ectodomain
result
antibodi
subsequ
human
design
enabl
futur
therapeut
use
human
use
biolay
interferometri
character
bind
kinet
affin
fab
fragment
prefus
niv
f
hev
f
ectodomain
trimer
immobil
surfac
biosensor
fab
bound
hev
fniv
f
equilibrium
dissoci
constant
nm
compar
equilibrium
dissoci
constant
nm
interact
fab
fig
supplementari
tabl
analysi
determin
associ
dissoci
rate
constant
indic
weaker
bind
affin
compar
larg
result
enhanc
dissoci
rate
supplementari
tabl
subsequ
neutral
assay
carri
use
authent
nivmalaysia
nivm
nivbangladesh
nivb
hev
virion
contain
plaqu
reduct
assay
perform
analyz
neutral
virus
preincub
vari
amount
antibodi
determin
mean
halfmaxim
inhibitori
concentr
nivm
nivb
hev
fig
result
show
potent
inhibit
infecti
niv
hev
two
hnv
respons
recurr
outbreak
lethal
enceph
respiratori
diseas
human
elucid
mechan
neutral
niv
hev
determin
cryoem
structur
stabil
niv
f
ectodomain
trimer
complex
antibodi
fab
fragment
resolut
fig
b
tabl
extend
data
assist
model
build
also
crystal
isol
fab
fragment
determin
structur
resolut
use
xray
crystallographi
tabl
agreement
featur
observ
cryoem
map
local
resolut
highest
niv
f
variabl
domain
includ
interfac
niv
f
wherea
fab
constant
domain
poorli
resolv
due
elbow
flexibl
constant
variabl
domain
model
final
model
includ
niv
f
residu
chain
break
residu
bind
quaternari
epitop
domain
iii
niv
f
globular
head
stoichiometri
three
fab
bound
f
trimer
fig
b
tabl
extend
data
cryoem
map
resolv
four
nlink
oligosaccharid
present
niv
f
protom
posit
reveal
recogn
glycanfre
epitop
f
surfac
could
detect
oligosaccharid
posit
cryoem
reconstruct
fig
b
agreement
previou
biochem
six
complementaritydetermin
region
cdr
light
chain
framework
region
contribut
paratop
buri
interfac
niv
f
epitop
mostli
resid
within
one
protom
fig
b
contact
niv
f
heptadrepeat
hra
via
electrostat
interact
fig
extend
data
bind
core
domain
iii
via
contact
residu
residu
subunit
fig
protrud
interfac
two
niv
f
protom
interact
segment
ctermin
central
helix
upstream
helix
neighbor
protom
fig
extend
data
comparison
unligand
niv
f
structur
reveal
bind
induc
local
reorgan
stabil
differ
conform
hra
residu
residu
extend
data
reli
atyp
bind
mode
niv
f
nearli
equal
contribut
heavi
light
chain
antibodi
buri
surfac
area
part
result
fact
make
greater
contribut
paratop
nine
residuelong
versu
buri
surfac
area
respect
contrast
canon
antibodyantigen
interfac
confirm
find
probe
niv
f
bind
abil
singlechain
scfv
chimer
construct
either
variabl
heavi
vh
variabl
light
vl
chain
replac
unrel
chain
human
scfv
librari
although
scfv
immunoprecipit
fulllength
niv
f
none
scfv
chimera
agreement
equival
contribut
bind
heavi
light
chain
observ
structur
fig
b
extend
data
structur
data
valid
use
sitedirect
mutagenesi
select
residu
particip
niv
f
epitop
follow
immunoprecipit
assess
residu
bind
extend
data
also
use
prefus
f
specif
antibodi
well
fusion
assay
probe
conform
integr
f
mutant
analyz
extend
data
c
niv
f
substitut
inhibit
recognit
probabl
explain
loss
interact
residu
visual
structur
furthermor
abrog
bind
niv
f
probabl
result
reduct
favor
interact
given
test
mutant
bound
antibodi
retain
wildtyp
f
fusion
activ
extend
data
c
conclud
observ
loss
bind
larg
result
specif
disrupt
interact
without
major
effect
overal
f
structur
analysi
structur
ration
observ
crossneutr
niv
hev
niv
f
residu
buri
upon
bind
strictli
conserv
variabl
posit
conserv
semiconserv
substitut
respect
fig
rna
virus
high
mutat
rate
hnv
could
yield
variant
abl
overcom
inhibit
exampl
show
passag
niv
hev
antihnv
g
antibodi
led
isol
viral
mutant
escap
neutral
respect
assess
possibl
gener
neutralizationescap
viru
mutant
aforement
bindingdefici
f
mutant
identifi
sitedirect
mutagenesi
passag
authent
niv
three
round
presenc
contain
plaqu
purifi
resist
virus
isol
viral
rna
five
niv
isol
reversetranscrib
cdna
sequenc
f
gene
five
niv
escap
mutant
harbor
f
substitut
find
support
aforement
mutagenesi
data
niv
f
complet
defect
bind
recombinantli
produc
f
mutant
observ
could
bind
maintain
abil
interact
promot
wildtyp
fusion
activ
extend
data
c
experi
full
agreement
structur
biochem
data
show
niv
could
escap
neutral
without
affect
fmediat
fusion
although
impact
identifi
substitut
viral
growth
known
structur
data
suggest
prevent
fusogen
conform
chang
lead
membran
fusion
lock
niv
f
prefus
state
antibodi
recogn
discontinu
epitop
span
two
neighbor
protom
present
prefus
f
base
conform
chang
observ
relat
parainfluenza
viru
postfus
f
respiratori
syncyti
viru
postfus
f
fig
b
furthermor
interact
hra
hinder
refold
latter
motif
contribut
format
elong
central
helix
observ
postfus
f
state
antibodymedi
molecular
stapl
strategi
involv
simultan
interact
protein
segment
close
prefus
f
far
apart
postfus
f
fig
b
conceptu
equival
disulfid
stapl
approach
implement
stabil
prefus
conform
measl
viru
respiratori
syncyti
viru
rsv
hev
piv
glycoprotein
final
predict
unfavor
steric
clash
would
occur
antibodi
bound
neighbor
protom
upon
f
refold
valid
hypothesi
lock
niv
f
prefus
conform
use
vitro
f
trigger
assay
entail
cleavag
wildtyp
niv
ectodomain
trimer
trypsin
limit
proteolysi
condit
recapitul
vivo
cathepsin
lmediat
product
incub
promot
refold
trypsincleav
prefus
f
trimer
postfus
previous
show
peptid
deriv
heptadrepeat
b
hrb
sequenc
niv
f
hev
f
prevent
complet
f
refold
potent
inhibitor
fusion
live
viru
furthermor
trigger
assay
carri
presenc
biotinyl
hrb
peptid
conform
intermedi
fusion
reaction
captur
could
use
report
f
activ
use
approach
demonstr
addit
trigger
assay
block
fusogen
conform
chang
concentrationdepend
manner
wherea
nonneutr
control
antibodi
specif
postfus
f
fig
subsequ
antibodi
affin
purif
protein
g
materi
captur
hrb
peptid
show
remain
bound
f
fig
support
hypothesi
trap
niv
f
prefus
conform
final
captur
f
intermedi
could
partial
rescu
rais
temperatur
indic
bind
stabil
niv
f
rais
energi
barrier
transit
postfus
state
fig
summari
structur
biochem
data
present
show
inhibit
fusogen
conform
chang
lock
f
prefus
state
rais
free
energi
activ
fusion
trigger
studi
mechan
action
context
fulllength
membraneembed
f
glycoprotein
carri
fusion
assay
presenc
vari
concentr
mab
observ
prevent
niv
f
hev
fmediat
membran
fusion
concentrationdepend
manner
consist
expect
trap
f
prefus
conform
actual
result
inhibit
membran
fusion
fig
g
paramyxoviru
pneumoviru
f
glycoprotein
key
player
viral
entri
promot
fusion
viral
host
membran
largescal
structur
f
conform
present
immun
system
major
determin
antibodi
respons
elicit
glycoprotein
previou
work
show
rsvneutral
activ
human
serum
confer
antibodi
specif
recogn
prefus
structurebas
physic
stabil
rsv
f
prefus
state
via
mutat
fusion
anoth
protein
domain
well
multival
display
comput
design
nanoparticl
platform
correl
increas
elicit
neutral
prefus
stabil
f
also
induc
greater
neutral
humor
immun
respons
postfus
f
parainfluenza
virus
mice
rhesu
howev
antibodi
present
sera
mice
immun
human
metapneumoviru
prefus
postfus
f
ectodomain
trimer
bound
similarli
either
protein
conform
equal
neutral
viru
infect
demonstr
prefus
postfus
f
share
neutral
epitop
previous
establish
fuse
trimer
motif
ctermin
end
niv
f
hev
f
ectodomain
result
product
prefus
stabil
trimer
could
elicit
neutral
antibodi
respons
hnv
f
mab
howev
character
molecular
level
sequenc
human
neutral
mab
demonstr
abil
crossneutr
authent
niv
hev
show
inhibit
membran
fusion
lock
f
prefus
conform
upon
bind
conform
quaternari
epitop
reorgan
fusion
reaction
mechan
action
ration
potent
neutral
niv
hev
entri
target
cell
reminisc
inhibit
rsv
via
bind
stabil
prefus
find
also
line
enhanc
properti
rsv
parainfluenza
viru
prefusionstabil
f
glycoprotein
candid
vaccin
immunogen
compar
correspond
postfus
accordingli
previous
develop
disulfidestabil
prefus
hev
correspond
prefus
niv
f
construct
engin
bear
promis
elicit
stronger
neutral
antibodi
titer
stabil
f
glycoprotein
ectodomain
prevent
refold
postfus
conform
far
human
mab
use
hnv
protect
studi
ferret
african
green
murin
antibodi
limit
clinic
use
due
short
serum
halflif
inabl
trigger
human
effector
function
risk
mount
antimous
antibodi
respons
success
engin
human
version
term
retain
compar
breadth
potenc
parent
mous
mab
inhibit
fmediat
membran
fusion
therefor
similar
antihnv
g
neutral
mab
could
potenti
use
prophylaxi
postexposur
therapi
individu
expos
niv
hev
use
compassion
basi
treat
individu
signific
hev
niv
exposur
risk
australia
usa
india
http
wwwwhointblueprintprioritydiseaseskeyactionnipahen
individu
show
evid
infect
known
health
complic
administr
mab
fact
use
human
despit
lack
clinic
trial
approv
fda
equival
agenc
emphas
urgent
need
develop
therapeut
countermeasur
highli
pathogen
hnv
fatal
rate
escap
mutant
isol
upon
hnv
passag
never
observ
vivo
efficaci
test
niv
hev
put
due
high
dose
antibodi
util
experi
conjunct
effect
adapt
immun
respons
subject
postul
similar
outcom
could
expect
compar
high
dose
mab
furthermor
neutral
escap
mutat
fspecif
mab
could
potenti
neg
impact
viral
growth
replic
virul
observ
mutant
obtain
antig
final
use
antibodi
cocktail
propos
ebola
sever
acut
respiratori
syndrom
coronaviru
sarscov
implement
commerci
avail
therapeut
hepat
c
viru
xtl
biopharmaceut
prevent
andor
limit
emerg
mutant
well
enhanc
neutral
breadth
suggest
similar
strategi
combin
antihnv
mab
target
multipl
antigen
site
g
f
could
implement
treat
futur
niv
hev
infect
cell
life
technolog
grown
express
medium
life
technolog
cultur
rpm
femal
human
embryon
kidney
cell
line
atcc
cell
kind
gift
g
quinnan
cultur
flask
dmem
fb
penicillinstreptomycin
mm
hepe
cell
atcc
grown
serumfre
medium
vpsfm
thermofish
helausu
helaatcc
atcc
maintain
dmem
qualiti
biolog
supplement
cosmic
calf
serum
hyclon
mm
lglutamin
helausu
cell
neg
kind
gift
maurelli
uniform
servic
univers
posit
atcc
previous
undergon
cytogenet
analysi
cell
line
authent
cell
test
mycoplasma
contamin
rabbit
antif
polyclon
antibodi
produc
spring
valley
laboratori
use
niv
f
ectodomain
trimer
fuse
immunogen
horseradish
peroxidaseconjug
rabbit
antispeptid
antibodi
purchas
bethyl
laboratori
antif
murin
monoclon
antibodi
produc
previous
ntermin
biotinyl
niv
f
hrb
peptid
residu
synthes
global
peptid
servic
niv
f
hev
f
ectodomain
construct
use
biolay
interferometri
niv
f
trigger
assay
includ
codon
optim
niv
f
isol
genbank
sequenc
access
hev
f
isol
ectodomain
residu
fuse
ctermin
follow
factor
xa
sequenc
stag
klketaaakferqhmd
clone
pcdna
hygro
cmv
vector
transient
express
use
freestyl
cell
epitop
map
convers
specif
residu
niv
f
alanin
serin
glutam
acid
aspart
acid
perform
via
sitedirect
mutagenesi
use
quickchang
ii
sitedirect
mutagenesi
kit
stratagen
templat
reaction
consist
ctermin
speptid
tag
version
codon
optim
fulllength
niv
f
isol
clone
pcdna
hygro
cmv
vector
mutationcontain
construct
sequenc
verifi
niv
f
ectodomain
construct
use
cryoem
experi
includ
human
codonoptim
niv
f
ectodomain
trimer
amino
acid
residu
flag
tag
dykdddk
introduc
residu
ctermin
motif
kind
gift
h
aguilarcarreno
construct
engin
subclon
pb
sk
vector
introduc
previous
describ
sitedirect
mutagenesi
use
quikchang
kit
agil
subsequ
subclon
pcagg
vector
transient
express
freestyl
cell
cdna
amplifi
hybridoma
use
superscript
iii
cell
direct
cdna
synthesi
kit
invitrogen
random
hexam
pcr
amplif
vh
vl
perform
use
cdna
templat
degener
forward
primer
signal
sequenc
conserv
framework
vh
vlencod
sequenc
revers
primer
end
constant
heavi
chain
constant
light
chain
cl
encod
pcr
product
clone
pcrblunt
iitopo
vector
invitrogen
transform
one
shot
chemic
compet
escherichia
coli
invitrogen
plasmid
extract
coloni
clone
pcr
product
sequenc
use
forward
revers
primer
engin
human
version
human
scfv
librari
first
gener
base
sequenc
similar
adapt
previous
describ
method
pcr
primer
employ
gener
naiv
human
scfv
librari
construct
peripher
blood
b
cell
sever
healthi
use
vh
subfamili
iii
vl
subfamili
primer
vh
vl
first
amplifi
separ
igm
cdna
librari
vh
use
forward
revers
primer
probe
vh
iii
restrict
site
sfii
ad
end
forward
primer
linker
sequenc
ad
end
revers
primer
vl
use
forward
revers
primer
probe
linker
sequenc
ad
end
forward
primer
restrict
site
sfii
ad
end
revers
primer
scfv
librari
assembl
overlap
pcr
combin
vh
vl
pcr
product
templat
use
vh
iii
sfii
forward
sfii
revers
primer
amplifi
scfv
clone
vector
harbor
ctermin
hexahistidin
tag
coloni
scfv
librari
grown
express
previous
select
best
express
clone
dna
sequenc
base
coomassi
blue
stain
western
blot
analysi
use
antihistidin
tag
antibodi
translat
human
scfv
fr
sequenc
align
human
conserv
human
residu
align
identifi
replac
homolog
posit
gener
human
version
name
gener
one
residu
two
residu
mutat
conserv
human
residu
base
sequenc
human
scfv
librari
mention
scfv
construct
design
vh
vl
separ
flexibl
linker
codonoptim
synthes
genscript
clone
promotermodifi
pcdna
hygro
immunoglobulin
chain
leader
sequenc
ctermin
speptid
tag
follow
hexahistidin
tag
igg
construct
vh
vl
clone
vector
harbor
cl
ch
fragment
separ
open
read
frame
independ
subsequ
entir
express
cassett
heavi
light
chain
amplifi
subclon
pcdna
hygro
cmv
vector
develop
stabl
cell
line
hek
cell
grown
transfect
differ
scfv
construct
use
fugen
transfect
reagent
roch
diagnost
cell
transfect
dna
fugen
per
well
confluent
sixwel
tissu
cultur
plate
follow
manufactur
instruct
h
post
transfect
cultur
medium
either
replac
select
medium
supplement
hygromycin
b
invitrogen
stabl
cell
line
develop
harvest
sprotein
agaros
emd
bioscienc
ninta
agaros
qiagen
precipit
transient
express
evalu
gener
cell
line
stabl
express
hygromycinresist
cell
subject
two
round
limit
dilut
clone
previous
product
purif
mous
igg
hybridoma
carri
previous
transient
express
carri
transfect
freestyl
suspens
cell
serumfre
freestyl
express
medium
invitrogen
shaker
flask
densiti
cell
use
transfect
reagent
invitrogen
follow
manufactur
protocol
product
stabl
cell
line
carri
cultur
freestyl
cell
express
ml
freestyl
express
medium
ml
shaker
flask
densiti
cell
transfect
cell
stabl
cell
allow
grow
addit
day
ml
cultur
medium
ad
everi
subsequ
day
cultur
supernat
express
igg
collect
centrifug
min
supernat
filter
low
protein
bind
membran
corn
pass
hitrap
protein
g
hp
column
ge
healthcar
bioscienc
equilibr
phosphatebuff
salin
qualiti
biolog
column
wash
five
column
volum
phosphatebuff
salin
bound
mab
elut
glycin
ph
follow
immedi
neutral
tri
ph
concentr
bufferexchang
phosphatebuff
salin
use
amicon
ultra
centrifug
concentr
millipor
fab
obtain
fragment
mous
igg
use
pierc
mous
fab
f
prepar
kit
accord
manufactur
protocol
fab
fragment
obtain
fragment
igg
lysc
proteas
emd
millipor
affin
purif
use
protein
agaros
resin
genscript
briefli
mg
igg
incub
lysc
h
reaction
quench
addit
pmsf
mm
final
concentr
undigest
fccontain
portion
sampl
remov
use
protein
resin
fabcontain
flowthrough
protein
affin
step
collect
fabcontain
fraction
concentr
purifi
use
superdex
gel
filtrat
column
equilibr
buffer
contain
mm
tri
ph
mm
nacl
solubl
niv
f
hev
f
produc
transient
transfect
freestyl
cell
densiti
cell
correspond
plasmid
use
transfect
reagent
millipor
optimem
thermofish
accord
manufactur
protocol
five
day
humidifi
shake
incub
maintain
cell
supernat
harvest
clarifi
cell
debri
centrifug
subsequ
affin
purif
carri
use
antiflag
resin
genscript
elut
mg
flag
peptid
dissolv
tri
buffer
ph
mm
nacl
sprotein
agaros
millipor
sigma
novagen
elut
citric
acid
ph
follow
immedi
neutral
tri
ph
elut
fraction
bufferexchang
mm
tri
buffer
ph
mm
nacl
use
kda
cutoff
centrifug
concentr
millipor
assay
perform
octet
red
instrument
fortebio
shake
rpm
measur
correct
subtract
background
signal
obtain
biosensor
without
immobil
hev
f
niv
f
speptid
tag
hev
f
niv
f
phosphat
buffer
salin
ph
dilut
mm
acet
buffer
ph
immobil
nhydroxysuccinimid
carbodiimid
hydrochlorid
nhsedc
nhsedcactiv
amin
reactiv
gener
fortebio
biosensor
sensor
quench
ethanolamin
fortebio
incub
kinet
buffer
kb
pb
bsa
tween
fortebio
establish
baselin
signal
nm
shift
hev
f
niv
fload
sensor
immers
solut
purifi
fab
dilut
kb
desir
concentr
kinet
analysi
nm
fab
nm
fab
curv
fit
perform
use
bind
model
determin
bind
kinet
fortebio
data
analysi
softwar
mean
kon
koff
valu
determin
global
fit
appli
data
experi
perform
twice
independ
niv
f
hev
f
protein
prepar
yield
ident
result
kinet
paramet
crystal
grown
hang
drop
set
mosquito
use
nl
protein
solut
nl
mother
liquor
contain
magnesium
chlorid
trishcl
ph
peg
diffract
dataset
collect
al
beamlin
process
resolut
use
structur
solv
molecular
replac
use
sarscov
search
model
coordin
subsequ
improv
complet
use
refin
qualiti
final
model
analyz
use
score
clashscor
percentag
poor
rotam
ramachandran
statist
favor
allow
crystallograph
data
collect
refin
statist
summar
tabl
purifi
flagtag
niv
f
ectodomain
combin
excess
molar
ratio
fab
incub
ice
h
inject
superos
increas
column
ge
healthcar
equilibr
buffer
contain
mm
tri
ph
mm
nacl
fraction
contain
complex
qualitycontrol
neg
stain
em
pool
bufferexchang
concentr
volum
purifi
flagtag
niv
f
fab
complex
concentr
mg
appli
onto
glowdischarg
cflat
cu
mesh
protochip
holey
carbon
grid
cover
thin
layer
continu
homemad
carbon
incub
grid
grid
plungefrozen
liquid
ethan
cool
liquid
nitrogen
use
fei
vitrobot
blot
time
chamber
kept
humid
blot
process
data
acquisit
carri
leginon
data
collect
fei
titan
krio
electron
microscop
oper
kv
equip
gatan
bioquantum
energi
filter
slit
width
ev
gatan
summit
camera
nomin
magnif
pixel
size
dose
rate
adjust
count
per
pixel
per
second
video
acquir
count
mode
fraction
frame
ms
total
micrograph
collect
defocu
rang
video
frame
align
carri
particl
automat
select
use
dog
within
appion
initi
defocu
paramet
estim
total
particl
pick
extract
process
box
size
preprocess
use
relion
referencefre
twodimension
classif
cryosparc
use
select
subset
particl
use
gener
initi
model
use
abinitio
reconstruct
function
map
subsequ
use
refer
run
classif
symmetri
relion
entir
dataset
particl
select
set
pick
particl
refin
use
relion
ctf
refin
relion
use
refin
perparticl
defocu
valu
particl
imag
subject
bayesian
polish
procedur
relion
refin
perform
anoth
round
ctf
refin
refin
particl
subsequ
subject
anoth
round
classif
relion
without
refin
angl
shift
particl
best
class
show
resolv
stem
use
nonuniform
refin
cryosparc
obtain
final
reconstruct
resolut
report
resolut
base
goldstandard
fsc
fourier
shell
correl
curv
correct
effect
soft
mask
highresolut
nois
local
resolut
estim
filter
carri
use
cryosparc
data
collect
process
paramet
list
tabl
ucsf
use
rigidbodi
fit
crystal
structur
niv
f
fab
crystal
structur
cryoem
densiti
model
subsequ
rebuilt
manual
use
refin
use
glycan
refin
reli
dedic
rosetta
protocol
use
physic
realist
geometri
base
prior
knowledg
saccharid
chemic
aid
use
sharpen
unsharpen
map
model
analyz
use
refin
statist
list
tabl
figur
gener
use
ucsf
evalu
bind
niv
f
mutant
differ
antibodi
subconflu
hek
cell
transfect
untag
fulllength
wild
type
one
mutant
niv
f
construct
use
fugen
transfect
reagent
describ
cell
harvest
h
post
transfect
lyse
buffer
contain
tri
ph
nacl
supplement
complet
proteas
inhibitor
cocktail
roch
clarifi
centrifug
clarifi
lysat
ad
igg
follow
slurri
protein
g
sepharos
sampl
incub
igg
slurri
sprotein
agaros
evalu
chain
bind
f
clarifi
untag
fulllength
fexpress
hek
cell
lysat
ad
scfvexpress
cultur
supernat
precipit
slurri
sprotein
agaros
case
immunoprecipitationpulldown
perform
overnight
sampl
wash
three
time
buffer
contain
triton
tri
ph
nacl
subsequ
boil
reduc
gel
electrophoresi
page
sampl
buffer
follow
western
blot
analys
captur
assay
perform
previous
addit
competit
step
presenc
increas
amount
igg
briefli
purifi
speptid
tag
niv
f
ectodomain
trimer
cleav
ng
trypsin
new
england
biolab
reaction
volum
buffer
overnight
gener
matur
subunit
reaction
stop
complet
proteas
inhibitor
cocktail
roch
subsequ
biotinyl
niv
f
hrb
peptid
ad
presenc
absenc
compet
igg
sampl
heat
min
niv
fhrb
complex
subsequ
pull
use
avidinagaros
slurri
h
thermo
fisher
scientif
indic
unbound
fraction
pull
protein
g
sepharos
sampl
wash
three
time
buffer
contain
triton
tri
ph
nacl
boil
reduc
sampl
buffer
analyz
precipit
product
sampl
appli
bt
invitrogen
follow
western
blot
detect
use
rabbit
antiniv
f
polyclon
antibodi
fusion
niv
f
g
glycoproteinexpress
effector
cell
permiss
target
cell
measur
use
previous
describ
briefli
plasmid
encod
speptid
tag
wildtyp
niv
f
mutant
f
niv
g
dna
controlmock
transfect
transfect
helausu
effector
cell
use
lipofectamin
ltx
plu
reagent
thermofisch
scientif
follow
day
transfect
cell
infect
vaccinia
virusencod
rna
polymeras
helaatcc
cell
serv
receptorposit
target
cell
also
infect
e
coli
lac
zencod
report
vaccinia
viru
cell
infect
multipl
infect
incub
overnight
cell
fusion
reaction
conduct
incub
target
effector
cell
mixtur
ratio
total
cell
per
well
ml
total
volum
plate
cytosin
arabinosid
sigmaaldrich
ad
fusion
reaction
mixtur
reduc
nonspecif
product
nonidet
emd
millipor
sigma
ad
final
concentr
h
aliquot
lysat
assay
ambient
temperatur
substrat
chlorophenol
roch
assay
perform
triplic
fusion
result
calcul
express
rate
activ
chang
optic
densiti
nm
versamax
micropl
reader
molecular
devic
equal
amount
leftov
fgexpress
effector
cell
fusion
reaction
lyse
clarifi
centrifug
lysat
subject
sprotein
agaros
precipit
follow
western
blot
evalu
express
level
f
mutant
compar
wild
type
individu
cell
fusion
reaction
mediat
mutant
convert
percentag
wildtyp
fusion
activ
normal
total
express
f
f
mutant
measur
densitometri
imag
western
blot
band
use
imagequanttl
softwar
ge
healthcar
bioscienc
normal
f
mutant
percentag
wildtyp
fusion
calcul
formula
normal
percentag
wildtyp
fusion
wildtyp
express
percentag
wildtyp
fusion
viru
infect
neutral
concentr
control
antibodi
antihiv
igg
antif
antif
determin
niv
hev
use
plaqu
reduct
assay
briefli
antibodi
serial
dilut
fivefold
ng
incub
target
pfu
plaqueform
unit
nivm
nivb
hev
min
viru
antibodi
mixtur
ad
individu
well
sixwel
plate
cell
plate
stain
neutral
red
two
day
infect
plaqu
count
h
stain
neutral
potenc
calcul
base
pfu
viru
well
without
antibodi
experi
perform
triplic
independ
viru
prepar
duplic
read
replic
mean
halfmaxim
inhibitori
concentr
calcul
previous
neutralizationresist
niv
mutant
gener
incub
tissu
cultur
infect
dose
viru
subneutr
concentr
igg
medium
h
inocul
onto
cell
presenc
igg
concentr
develop
cytopath
effect
monitor
h
progeni
virus
harvest
igg
treatment
repeat
two
addit
time
cytopath
effect
develop
slowli
passag
virus
third
passag
plaqu
purifi
presenc
igg
neutral
resist
virus
isol
experi
perform
duplic
f
g
glycoprotein
gene
five
individu
plaqu
sequenc
neutral
titer
wild
type
neutralizationresist
viru
determin
use
microneutr
assay
briefli
igg
serial
dilut
two
fold
incub
wildtyp
neutralizationresist
niv
h
viru
antibodi
ad
plate
cell
per
well
four
well
per
antibodi
dilut
well
check
cytopath
effect
three
day
post
infect
mean
halfmaxim
inhibitori
concentr
determin
mab
concentr
least
well
show
cytopath
effect
inform
experiment
design
avail
natur
research
report
summari
link
articl
method
addit
refer
natur
research
report
summari
sourc
data
statement
code
data
avail
associ
access
code
avail
